AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Disheveled-associated activator of morphogenesis 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q86T65

UPID:

DAAM2_HUMAN

Alternative names:

-

Alternative UPACC:

Q86T65; G5EA45; Q5T4T8; Q5T4U0; Q9NQI5; Q9Y4G0

Background:

Disheveled-associated activator of morphogenesis 2 is a pivotal regulator of the Wnt signaling pathway, essential for developmental processes such as dorsal patterning, symmetry determination, and central nervous system myelination. It functions downstream of Wnt ligands and upstream of beta-catenin, facilitating Wnt receptor signalosome formation and enhancing Wnt activity.

Therapeutic significance:

Linked to Nephrotic syndrome 24, a renal disease leading to end-stage renal failure, this protein's understanding could pave the way for innovative treatments targeting the Wnt signaling pathway to combat kidney diseases and potentially other Wnt-related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.